Ed Biotech announced that recently, the company signed an accompanying diagnosis cooperation agreement with BOEHRINGER INGELHEIM INTERNATIONAL (hereinafter referred to as “Boehringer Ingelheim”). The accompanying diagnostic products independently developed by the company will be used in China to screen and identify non-small cell lung cancer patients (NSCLC) most likely to benefit from targeted therapy.
艾德生物：与勃林格殷格翰签署伴随诊断合作协议
Ed Biotech: Signed a cooperation agreement with Boehringer Ingelheim to accompany diagnosis
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.